HighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results

Bulletin Express

03/13

HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated financial results for the year ended 31 December 2025 and authorise their publication. Additional routine business matters may also be addressed at the meeting.

The board currently consists of two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng) and three independent non-executive directors (Mr. Tan Bo, Dr. Li Jin and Mr. Hung Tak Wai).

The company will disclose the audited annual results following board approval on the scheduled date.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1152794578"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152794578\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152794578?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152794578","market":"hk","top_or_hot":-1,"title":"HighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results","media":"Bulletin Express","content":"<p>HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated financial results for the year ended 31 December 2025 and authorise their publication. Additional routine business matters may also be addressed at the meeting.</p>\n<p>The board currently consists of two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng) and three independent non-executive directors (Mr. Tan Bo, Dr. Li Jin and Mr. Hung Tak Wai).</p>\n<p>The company will disclose the audited annual results following board approval on the scheduled date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-13 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated financial results for the year ended 31 December 2025 and authorise their publication. Additional routine business matters may also be addressed at the meeting.</p>\n<p>The board currently consists of two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng) and three independent non-executive directors (Mr. Tan Bo, Dr. Li Jin and Mr. Hung Tak Wai).</p>\n<p>The company will disclose the audited annual results following board approval on the scheduled date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02511","symbol_name":"君圣泰医药-B","start_time":0,"source_url":"","article_id":"1152794578","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152794578","pubTimestamp":1773396254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02511":"君圣泰医药-B"},"translate_title":"HighTide Therapeutics-B(2511)计划于2026年3月27日召开董事会会议，批准2025财年经审计业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":1},"content_text":"HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated financial results for the year ended 31 December 2025 and authorise their publication. Additional routine business matters may also be addressed at the meeting.\nThe board currently consists of two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng) and three independent non-executive directors (Mr. Tan Bo, Dr. Li Jin and Mr. Hung Tak Wai).\nThe company will disclose the audited annual results following board approval on the scheduled date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}